1.
Intern Med
; 62(13): 2013-2017, 2023 Jul 01.
Article
in English
| MEDLINE | ID: covidwho-2290800
ABSTRACT
A Japanese man experienced three episodes of hypovolemic shock and was diagnosed with systemic capillary leak syndrome (SCLS). He developed SCLS exacerbation 2 days after receiving a second dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine, 1 year after the third episode. After fluid therapy and albumin administration, we initiated terbutaline and theophylline prophylaxis for SCLS. A literature review revealed that SCLS attacks often occur 1-2 days after the second COVID-19 vaccination. Patients with a history of SCLS should avoid COVID-19 vaccination and be carefully monitored for 1-2 days if they receive the vaccine.
Subject(s)
COVID-19 Vaccines , COVID-19 , Capillary Leak Syndrome , Humans , Male , BNT162 Vaccine , Capillary Leak Syndrome/etiology , Capillary Leak Syndrome/diagnosis , Capillary Leak Syndrome/drug therapy , COVID-19/prevention & control , COVID-19 Vaccines/adverse effects , Terbutaline
2.
Ann Intern Med
; 174(10): 1476-1478, 2021 10.
Article
in English
| MEDLINE | ID: covidwho-1268406
Subject(s)
COVID-19 Vaccines/adverse effects , COVID-19/prevention & control , Capillary Leak Syndrome/diagnosis , Aged , Capillary Leak Syndrome/drug therapy , Cardiovascular Agents/therapeutic use , Disease Progression , Female , Humans , Immunoglobulins, Intravenous/therapeutic use , Male , Middle Aged , Pandemics , Risk Factors , SARS-CoV-2 , Terbutaline/therapeutic use , Theophylline/therapeutic use
3.
J Allergy Clin Immunol Pract
; 8(7): 2450-2452, 2020.
Article
in English
| MEDLINE | ID: covidwho-1121998
4.
J Allergy Clin Immunol Pract
; 8(7): 2450, 2020.
Article
in English
| MEDLINE | ID: covidwho-88463